Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    16051328 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
Condition: Sarcoma
Interventions: Biological: sargramostim;   Drug: cisplatin;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: mitomycin C

Indicates status has not been verified in more than two years